Have a feature idea you'd love to see implemented?
Let us know!
GH Guardant Health Inc
Price (delayed)
$23.1
Market cap
$2.84B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.13
Enterprise value
$3.12B
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health
Highlights
Guardant Health's revenue has increased by 26% YoY and by 7% from the previous quarter
The gross profit has grown by 22% YoY and by 6% from the previous quarter
The EPS is up by 16% year-on-year but it has declined by 4.3% since the previous quarter
Guardant Health's net income has decreased by 6% QoQ but it has increased by 3.4% YoY
GH's equity has shrunk by 102% QoQ and by 101% YoY
Guardant Health's quick ratio has decreased by 14% YoY
Key stats
What are the main financial stats of GH
Market
Valuations
Earnings
Shares outstanding
123.02M
Market cap
$2.84B
Enterprise value
$3.12B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
Revenue
$643.81M
EBIT
-$487.69M
EBITDA
-$444.45M
Free cash flow
-$299.27M
Per share
Balance sheet
Liquidity
EPS
-$4.13
Free cash flow per share
-$2.44
Book value per share
-$0.01
Revenue per share
$5.26
TBVPS
$13.05
Total assets
$1.61B
Total liabilities
$1.61B
Debt
$1.31B
Equity
-$1.61M
Working capital
$1.09B
Debt to equity
-814.29
Current ratio
6.4
Quick ratio
5.63
Net debt/EBITDA
-0.63
Margins
Efficiency
Dividend
EBITDA margin
-69%
Gross margin
59.9%
Net margin
-76.2%
Operating margin
-79.4%
Return on assets
-28.5%
Return on equity
-432.7%
Return on invested capital
-25.9%
Return on capital employed
-34.6%
Return on sales
-75.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GH stock price
How has the Guardant Health stock price performed over time
Intraday
6.01%
1 week
13.12%
1 month
0.7%
1 year
-8.8%
YTD
-14.6%
QTD
0.7%
Financial performance
How have Guardant Health's revenue and profit performed over time
Revenue
$643.81M
Gross profit
$385.96M
Operating income
-$511.36M
Net income
-$490.76M
Gross margin
59.9%
Net margin
-76.2%
The company's operating margin rose by 26% YoY and by 10% QoQ
Guardant Health's revenue has increased by 26% YoY and by 7% from the previous quarter
The net margin is up by 23% year-on-year
The gross profit has grown by 22% YoY and by 6% from the previous quarter
Growth
What is Guardant Health's growth rate over time
Valuation
What is Guardant Health stock price valuation
P/E
N/A
P/B
N/A
P/S
4.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
The EPS is up by 16% year-on-year but it has declined by 4.3% since the previous quarter
GH's equity has shrunk by 102% QoQ and by 101% YoY
The P/S is 81% below the 5-year quarterly average of 21.6 and 23% below the last 4 quarters average of 5.4
Guardant Health's revenue has increased by 26% YoY and by 7% from the previous quarter
Efficiency
How efficient is Guardant Health business performance
The ROE has plunged by 76% from the previous quarter
Guardant Health's ROIC has decreased by 34% YoY and by 21% from the previous quarter
The return on sales is up by 23% year-on-year
GH's ROA is down by 10% since the previous quarter but it is up by 7% year-on-year
Dividends
What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GH.
Financial health
How did Guardant Health financials performed over time
Guardant Health's quick ratio has decreased by 14% YoY
Guardant Health's total assets has decreased by 13% YoY and by 6% from the previous quarter
GH's equity has shrunk by 102% QoQ and by 101% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.